Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 21, 2017. The document serves as a transaction notification regarding changes in the notional interest of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions relate to the re-investment of dividends paid on April 13, 2017, under the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data provided relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: All transactions occurred at a uniform price of £16.47 per share.
- Transaction Date: April 18, 2017.
- Total Volume: The filing details transactions for 11 executives, with individual aggregated volumes ranging from approximately 361 shares to 6,737 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for the listed executives. These changes are not the result of open market purchases but are automatic increases resulting from the re-investment of dividends. There are no material changes to the company's operations, financial position, or capital structure reported in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of executive share plan activity.
Important Facts for Investors
- The filing confirms that dividends were paid to shareholders on April 13, 2017.
- Eleven senior executives, including the CEO (Ms E Walmsley) and CFO (Mr S Dingemans), participated in the dividend re-investment plan.
- The share price used for the re-investment was £16.47.
- This document does not provide any data on GSK's overall financial performance for the period.